Press release
Anti-CD20 Antibody Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight
Anti-CD20 Antibody Clinical Trials
Key Takeaways from the Anti-CD20 Antibody Pipeline Report
• DelveInsight's Anti-CD20 Antibody pipeline report depicts a robust space with 20+ Anti-CD20 Antibody companies working to develop 20+ pipeline therapies for Anti-CD20 Antibody treatment.
• The leading companies working in the Anti-CD20 Antibody market include TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
• Promising Anti-CD20 Antibody Pipeline Therapies in the various stages of development include Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.
• April 2024: Shayna Sarosiek- Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Predominantly Demyelinating Neuropathy With or Without Anti-MAG.
• April 2024:- Hoffmann-La Roche- A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis.
• April 2024:- Regeneron Pharmaceuticals- A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3).
Request a sample and discover the recent advances in Anti-CD20 Antibody Treatment Drugs @ Anti-CD20 Antibody Pipeline Report- https://www.delveinsight.com/sample-request/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
The Anti-CD20 Antibody pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anti-CD20 Antibody drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anti-CD20 Antibody clinical trial landscape.
Anti-CD20 Antibody Overview
Anti-CD20 antibodies are a class of therapeutic agents designed to target the CD20 protein found on the surface of B-cells, a type of white blood cell involved in the immune response. These antibodies are used primarily in the treatment of B-cell malignancies such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), as well as autoimmune diseases like rheumatoid arthritis and multiple sclerosis.
The mechanism of action involves binding to the CD20 antigen on B-cells, leading to their destruction through various pathways, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. This depletion of B-cells helps to reduce the abnormal immune response in autoimmune diseases and to control the proliferation of malignant B-cells in cancers.
Rituximab was the first anti-CD20 antibody approved and has been followed by other antibodies like obinutuzumab, ofatumumab, and ocrelizumab, each with unique modifications to improve efficacy and reduce side effects. These therapies have transformed the treatment landscape for B-cell disorders, providing significant clinical benefits and improving survival rates.
Despite their effectiveness, anti-CD20 antibodies can have side effects, including infusion reactions, infections due to immunosuppression, and potential cardiovascular risks. Ongoing research aims to develop next-generation anti-CD20 antibodies with enhanced safety profiles and greater therapeutic potential.
Find out more about Anti-CD20 Antibody Treatment Landscape @ Drugs for Anti-CD20 Antibody Treatment- https://www.delveinsight.com/sample-request/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Anti-CD20 Antibody Emerging Drugs Profile
• Ublituximab: TG therapeutics
• Glofitamab: Roche
Anti-CD20 Antibody Pipeline Therapeutics Assessment
The Anti-CD20 Antibody pipeline report proffers an integral view of the Anti-CD20 Antibody emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Anti-CD20 Antibody Pipeline Therapies @ Anti-CD20 Antibody Clinical Trials Assessment- https://www.delveinsight.com/sample-request/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Anti-CD20 Antibody Pipeline Report
• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Anti-CD20 Antibody Companies- TG Therapeutics, Roche, Genmab/ Novartis, Biocad, Regeneron Pharmaceuticals, IGM Biosciences, Genentech, MENTRIK Biotech, Xencorm, KindredBio, Boehringer Ingelheim, Bioxpress therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, BioThera solutions, and others.
• Anti-CD20 Antibody Pipeline Therapies- Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab, Ofatumumab, Cyclophosphamide, Doxorubicin, Acalabrutinib, Obinutuzumab and Pixantrone, and others.
Dive deep into rich insights for new drugs for Anti-CD20 Antibody Treatment, Visit @ Anti-CD20 Antibody Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/anti-cd20-antibody-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Anti-CD20 Antibody: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Anti-CD20 Antibody - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Anti-CD20 Antibody Collaboration Deals
9. Late Stage Products (Preregistration)
10. Ublituximab: TG therapeutics
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Odronextamab: Regeneron Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Early stage products (Phase I)
16. IGM 2323: IGM Biosciences
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Anti-CD20 Antibody Key Companies
20. Anti-CD20 Antibody Key Products
21. Anti-CD20 Antibody- Unmet Needs
22. Anti-CD20 Antibody- Market Drivers and Barriers
23. Anti-CD20 Antibody- Future Perspectives and Conclusion
24. Anti-CD20 Antibody Analyst Views
25. Anti-CD20 Antibody Key Companies
26. Appendix
Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Acute Intermittent Porphyria Market: https://www.delveinsight.com/report-store/acute-intermittent-porphyria-market
• Acute Ischemic Stroke Ais Market: https://www.delveinsight.com/report-store/acute-ischemic-stroke-ais-market
• Acute On Chronic Liver Failure Aclf Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Age-related Macular Degeneration Market: https://www.delveinsight.com/report-store/age-related-macular-degeneration-amd-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Athlete's Foot Market: https://www.delveinsight.com/report-store/athletes-foot-market
• Biliary Atresia Market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
Contact Us:
Ankit Nigam
Marketing Manager
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-CD20 Antibody Clinical Trials Assessment 2024: FDA Approvals, Drugs, Clinical Trials, Therapeutic Analysis, and Companies by DelveInsight here
News-ID: 3560583 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for CD20
Anti-CD20 Monoclonal Antibodies (MAbs) Market Is Booming So Rapidly | Pfizer, Te …
The Global Anti-CD20 Monoclonal Antibodies (MAbs) Market Size is estimated at $12.8 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 10.2% to reach $30.7 Billion by 2034.
The latest study released on the Global Anti-CD20 Monoclonal Antibodies (MAbs) Market by USD Analytics Market evaluates market size, trend, and forecast to 2034. The Anti-CD20 Monoclonal Antibodies (MAbs) market study covers significant research data and proofs to…
Anti-CD20 Antibody Pipeline: 20+ Trailblazing Companies Powering the Future of T …
The anti-CD20 antibody market is entering a new era of innovation, driven by over 20 leading biotech and pharma players, including Bioxpress Therapeutics, 3SBio, Sinocelltech, Alopexx Oncology, Pfizer, Protheragen, Biogen Idec/Genentech, and BioThera Solutions. These visionaries are reshaping treatment paradigms with next-gen therapies that promise greater precision and better outcomes.
DelveInsight's "Anti-CD20 Antibody Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Anti-CD20 Antibody market. The…
CD20 Antibody Market Forecast 2025-2034: Analysing Major Trends, Opportunities, …
Which drivers are expected to have the greatest impact on the over the cd20 antibody market's growth?
The increasing incidence of B-cell malignancies is also expected to propel the growth of the CD-20 antibody market. These malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, are on the rise due to factors like aging and genetic predisposition. CD20 antibodies, such as rituximab, target malignant B-cells to improve therapeutic outcomes. According to…
Anti-CD20 Antibody Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Anti-CD20 Antibody Pipeline Insight 2024" report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from…
Anti-CD20 Antibody Pipeline, FDA Approvals, Clinical Trials Developments and Com …
DelveInsight's, "Anti-CD20 Antibody Pipeline Insight" report provides comprehensive insights about 20+ Anti-CD20 Antibody companies and 20+ pipeline drugs in Anti-CD20 Antibody pipeline landscape. It covers the Anti-CD20 Antibody pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anti-CD20 Antibody pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the…
CD20 Monoclonal Antibodies Market is growing at a healthy CAGR of 8.4% by 2028
The CD20 monoclonal antibodies market is estimated to gain market growth in the upcoming forecasted years. Data Bridge Market Research analyses the market is growing at a healthy CAGR of 8.4% in the above-mentioned research forecast period. The increasing R&D in generating potent CD20 monoclonal antibodies will drive the market.
The demand of CD20 monoclonal antibodies market has increased significantly because of advancements in technology, increasing demand of immunotherapy and fewer…
